Indivior Sets New Financial Expectations After Solid Q2 2025 Performance
Indivior Sets New Financial Expectations After Solid Q2 2025 Performance
Indivior PLC, a leading global pharmaceutical company focused on improving the lives of those struggling with opioid use disorder (OUD), has reported impressive financial outcomes for the second quarter of 2025. The company's total net revenue reached $302 million, a modest increase from $299 million in the same quarter of the previous year. A significant contributor to this positive trend was the revenue generated from SUBLOCADE®, which saw net sales totaling $209 million, marking a 9% increase year-over-year. This growth trajectory has led Indivior to revise its financial guidance for the upcoming fiscal year, reflecting heightened expectations based on the successful performance of its products.
CEO Joe Ciaffoni expressed confidence in the company’s direction,
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.